Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

The influence of advanced age on outcomes in patients with diffuse large B-cell lymphoma treated with CAR-T therapy.

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMuqtasid Aftab KhanUniversity of Alabama in HuntsvilleNSNanda Krishnan SivaWest Virginia UniversitySWShanawar WarisWest Virginia University

Discussion

Loading...

Member takes

Implication

Multicenter cohort study shows similar survival and lower toxicity in elderly patients with DLBCL treated with CAR-T therapy, suggesting age should not limit treatment eligibility.

Key Points

  • This study aims to evaluate how advanced age affects survival and toxicity outcomes in diffuse large B-cell lymphoma patients treated with CAR-T therapy.
  • Multicenter retrospective cohort study using the TriNetX database.
  • Patients aged ≥75 years with DLBCL were compared to a propensity score-matched cohort aged 18–65.
  • Primary outcomes included overall survival rates and the incidence of cytokine release syndrome, ICANS, and infections.
  • No statistically significant difference in one-year (HR: 0.89, 95% CI [0.63-1.26]) or three-year overall survival (HR: 1.00, 95% CI [0.74-1.36]) between age groups.
  • Lower risk of cytokine release syndrome in patients ≥75 years (RR: 0.84, 95% CI [0.72–0.98]).
  • Reduced risk of infection within 100 days post-CAR-T infusion for patients ≥75 years (RR: 0.75, 95% CI [0.58–0.95]).

Cite This Study

Khan et al. (2026) studied this question.

synapsesocial.com/papers/6a192d7efab5b468c4416670https://doi.org/10.1200/jco.2026.44.16_suppl.7034
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis2025
  2. 2Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study2024 · 37 citations
  3. 3Anti‐ CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study2024 · 10 citations
  4. 4CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.2026
  5. 5Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis2025